A recent study on 15 patients with synovial sarcoma demonstrated very low prevalence of tumor-specific fusion transcripts in peripheral blood specimens. Our results in an independent cohort of 38 patients with synovial sarcoma support these findings. Synovial sarcoma patients could greatly benefit from a non-invasive monitoring of tumor burden by liquid biopsies. However, given the low detection rate of SS18-SSX1/2 in circulation, we conclude that alternative markers other than the tumor-type specific fusion transcripts should be considered.
CITATION STYLE
Przybyl, J., Van De Rijn, M., & Rutkowski, P. (2019, March 14). Detection of SS18-SSX1/2 fusion transcripts in circulating tumor cells of patients with synovial sarcoma. Diagnostic Pathology. BioMed Central Ltd. https://doi.org/10.1186/s13000-019-0800-x
Mendeley helps you to discover research relevant for your work.